Michael T. Rudd
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Synthetic Organic Chemistry Methods, Hepatitis C virus research, Catalytic Alkyne Reactions, HIV/AIDS drug development and treatment, Asymmetric Synthesis and Catalysis
Most-Cited Works
- → Ruthenium‐Catalyzed Reactions—A Treasure Trove of Atom‐Economic Transformations(2005)529 cited
- → MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants(2012)254 cited
- → Structural basis for selectivity and diversity in angiotensin II receptors(2017)212 cited
- → Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor(2012)201 cited
- → Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor(2010)176 cited
- → MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease(2009)141 cited
- → Ruthenium‐katalysierte Reaktionen – eine Schatzkiste für atomökonomische Umwandlungen(2005)134 cited
- → Molecular Modeling Based Approach to Potent P2−P4 Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease(2008)134 cited
- → Ruthenium-Catalyzed Cycloisomerizations of Diynols(2005)125 cited
- → Hepatitis C virus NS3/4a protease inhibitors(2016)120 cited